Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.58 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.57 |
| ▸ | CTSB | P07858 | 2/20 | 0.56 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.53 |
| ▸ | TACR1 | P25103 | 3/20 | 0.51 |
| ▸ | CTSL | P07711 | 3/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | PLAT | P00750 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2577615 | 1.00 | TRPM8 (0.58) | TRPM8CTRB1CTSBSPPL2ATACR1 | |
| SCHEMBL6500127 | 1.00 | TRPM8 (0.58) | TRPM8CTRB1CTSBSPPL2ATACR1 | |
| SCHEMBL3023446 | 1.00 | TRPM8 (0.58) | TRPM8CTRB1CTSBSPPL2ATACR1 | |
| SCHEMBL6654213 | 1.00 | TRPM8 (0.58) | TRPM8CTRB1CTSBSPPL2ATACR1 | |
| SCHEMBL6496841 | 0.93 | TRPM8 (0.52) | TRPM8CTRB1CTSBSPPL2ATACR1 | |
| SCHEMBL6486738 | 0.93 | TRPM8 (0.52) | TRPM8CTRB1CTSBSPPL2ATACR1 | |
| SCHEMBL7267940 | 0.91 | ATM (0.58) | TRPM8CTRB1CTSBSPPL2ACTSL | |
| SCHEMBL5650179 | 0.88 | KLK5 (0.48) | TRPM8CTRB1CTSBSPPL2ACTSL | |
| SCHEMBL7275756 | 0.88 | CTSL (0.55) | TRPM8CTRB1CTSBSPPL2ACTSL | |
| SCHEMBL6812568 | 0.87 | TRPM8 (0.60) | TRPM8CTRB1CTSBSPPL2ATACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210603-A1 | NOVEL SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | TUNG ROGER D | 2010-08-19 | — | — | US | disclosed |
| US-7608632-B2 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080293727-A1 | Novel sulfonamide inhibitors of aspartyl protease | TUNG ROGER D | 2008-11-27 | — | — | US | disclosed |
| WO-2008038050-A2 | REDUCTION OF ALPHA-HALO KETONES | ALMAC SCIENCES LIMITED (GB) | 2008-04-03 | — | — | WO | disclosed |
| US-7321063-B2 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-22 | — | — | US | disclosed |
| US-20060189810-A1 | Novel sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-24 | — | — | US | disclosed |
| US-RE38796-E1 | Process for producing 3-amino-2-oxo-1-halogenopropane derivatives | AJINOMOTO CO.,INC. (JP) | 2005-09-13 | — | — | US | disclosed |
| US-20040167116-A1 | Novel sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2004-08-26 | — | — | US | disclosed |
| US-6720335-B2 | VIRICIDES | VERTEX PHARMACEUTICALS INCORPORATED | 2004-04-13 | — | — | US | disclosed |
| EP-0885887-B1 | Sulfonamide inhibitors of HIV-Aspartyl protease | VERTEX PHARMA (US) | 2003-05-28 | — | — | EP | disclosed |
| US-6004957-A | VIRICIDES FOR HUMAN T-CELL LEUKEMIA/LYMPHOMA VIRUS | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1999-12-21 | — | — | US | disclosed |
| US-5977137-A | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1999-11-02 | — | — | US | disclosed |
| US-5902887-A | Process for producing 3-amino-2-oxo-1-halogenopropane derivatives | AJINOMOTO CO., INC. (JP) | 1999-05-11 | — | — | US | disclosed |
| EP-0659181-B1 | SULFONAMIDE INHIBITORS OF HIV-ASPARTYL PROTEASE | VERTEX PHARMA (US) | 1999-04-07 | — | — | EP | disclosed |
| US-5856353-A | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1999-01-05 | — | — | US | disclosed |
| EP-0885887-A2 | Sulfonamide inhibitors of HIV-Aspartyl protease | Vertex Pharmaceuticals Incorporated (US) | 1998-12-23 | — | — | EP | disclosed |
| US-5783701-A | ANTI-HIV VIRICIDES | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-07-21 | — | — | US | disclosed |
| US-5767316-A | REACTING PROTECTED AMINO ACID WITH ALKALI METAL ENOLATE OF ACETATE, HALOGENATING, HYDROLYZING, DECARBOXYLATING | AJINOMOTO CO., INC. (JP) | 1998-06-16 | — | — | US | disclosed |
| US-5723490-A | THF-containing sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-03-03 | — | — | US | disclosed |
| EP-0774453-A1 | Process for producing 3-amino-2-oxo-1-halogenopropane derivatives | Ajinomoto Co., Inc. (JP) | 1997-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167116-A1 | Novel sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | TRPM8 2726/4885CTRB1 250/4885CTSB 139/4885 |
| US-20100210603-A1 | NOVEL SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | SPINT2, PRSS1, DNPEP | TRPM8 2726/4885CTRB1 250/4885CTSB 139/4885 |
| US-20060189810-A1 | Novel sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | TRPM8 2726/4885CTRB1 250/4885CTSB 139/4885 |
| US-20080293727-A1 | Novel sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | TRPM8 2726/4885CTRB1 250/4885CTSB 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.